Current issue #12, 2017

Fiscal discipline of vaccine manufacturer Fort not to trigger questions

In early 2017, eight debt recovery suits were filed against Fort LLC totaling more than 10 m RUB. New claims are likely to follow as well because vaccine transporting companies are not satisfied with how the manufacturer pays for their services. At the same time, National Immunobiological Company (NatsImBio), Fort’s principle partner and co-owner, calls for calm, and asserts that vaccine delivery interruptions will not happen.

[PharmVestnik # 12, 11/04/2017, p. 1, cont’d p. 5]

Expert opinion on innovative medicine development in Russia

The Public Chamber hosted a roundtable “Medicine of the future; science and technologies”. Experts representing Rusnano and other innovation institutes noted that the gap between Russia and leading counties in the field of innovative pharmaceuticals keeps growing. On the other hand, there are growth points as well, and if the government invests effort, a contribution can be made in longer life expectancy, and better quality of life.

[PharmVestnik # 12, 11/04/2017, p. 2]

Industrial clusters wait for fair government support

Industrial clusters operating in Russia temporarily stopped receiving federal funding. One funding program has been completed, while the other has not come into effect yet. As a result, e.g., in Kaluga Pharmaceutical Cluster, the project aimed at creating an educational center for the cluster participants has been suspended. At the same time, there are not only infrastructural issues on the agenda. The market players are mostly concerned with the opportunities of selling pharmaceuticals manufactured.

[PharmVestnik # 12, 11/04/2017, p. 3]

Ministry of Industry and Trade to subsidize pediatric drug manufacturers

Drafts amendments to the resolution describing the rules of allocating federal subsidies for local pharmaceutical manufacturers within the framework of the government program Pharma-2020 have been subjected to public hearings. In particular, it is proposed to subsidize setting up of pediatric drug manufacture projects. An impetus for drafting this document has been given by Premier Dmitry Medvedev’s assignment. Experts comment that large pharma companies that already have relevant manufacturing capacities may be potentially interested in this segment. However, the Ministry of Health interjects that the pediatric drug production issue has been burning for a long time, but businesses consider manufacture of pediatric dosage forms unp...